Archives

Slows clinical progression at 76 weeks for those with low/medium tau and the combined low/medium and high tau pathology population

Survival estimates that exclude the effects of coexisting conditions lead to underestimation, overestimation of survival

Worse overall survival seen for prolonged median time from surgery to initiation of postoperative radiation

More than half of patients in remission six years after surgery, regardless of weight loss

Risk reduced by more than one-third versus matched individuals without surgery

Women with atrial fibrillation and normal baseline cognition had higher risk of disease progression from normal to MCI, MCI to dementia

Normalization of alanine aminotransferase also seen with bulevirtide 2- or 10-mg

Improvements also seen in NASH resolution with pegozafermin 15 or 30 mg weekly, or 44 mg every two weeks

Higher HbA1c, two-hour plasma glucose linked to significantly increased risk of retinopathy in children without T2D

Substantial reductions seen in body weight with retatrutide treatment for 48 weeks in phase 2 trial